Taipei, Taiwan | January 09, 2006
YC Biotech announced today that it has successfully assisted its partner, SL Bio, in reaching regulatory alignment with the U.S. FDA regarding the development pathway for CTA-001, following a productive INTERACT meeting (Meeting ID: 22044). This engagement provided key expert guidance from the Agency, significantly accelerating the program’s transition toward clinical development.
CTA-001 consists of autologous T cells expanded ex-vivo and incubated with anti-CD3/anti-CD19 bispecific antibodies, designed for the treatment of relapsed or refractory CD19+ hematologic malignancies. During the meeting, the companies established a clear regulatory path with the FDA regarding Chemistry, Manufacturing, and Controls (CMC), safety assessments, and the proposed clinical trial design.
“Achieving regulatory alignment with the FDA is a pivotal endorsement of our development strategy,” stated YC Biotech. “By obtaining this key guidance, we have confirmed the regulatory roadmap for CTA-001. We will now integrate these insights to streamline the path toward a successful future IND submission.”
*Image AI-generated, for illustration purposes only